Richard Stone

发表

Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.

Pascal Furet, Guido Bold, Arghya Ray, 2008, Blood.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Francisco Cervantes, Ryuzo Ohno, Richard E. Clark, 2013, Blood.

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.

Pierre Fenaux, R. Stone, P. Fenaux, 2007, Blood.

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

Doriano Fabbro, D. Fabbro, J. Griffin, 2005, Blood.

Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia

Stephen L. George, Edward J. Lee, S. George, 1995 .

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Peter Marynen, Rafeul Alam, Jan Cools, 2003, The New England journal of medicine.

The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112.

D. DeAngelo, I. Galinsky, R. Stone, 2005, Cancer research.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

James Allison, Stephen Forman, Massimo Cristofanilli, 2015, Mayo Clinic proceedings.

Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia

David C. Atkins, Bob Löwenberg, David Atkins, 2007, Clinical Cancer Research.

An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome

Pablo Tamayo, Benjamin L Ebert, Todd R Golub, 2008, PLoS medicine.